Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
A ‘Head Spinning’ Year: How US FDA’s Ad Enforcement Blitz Reshaped Drug Promotion
Jan 05 2026
•
By
Sue Sutter
perspectives 2026
Biopharma companies should be more cautious, but need not hide under the bed, when it comes to advertising and promotion in 2026.
(Shutterstock)
More from Pink Sheet Perspectives
More from Marketing & Advertising